Prophylactic treatment with oral azithromycin in cancer patients during the COVID-19 pandemic (OnCoVID): a randomized, single-blinded, placebo-controlled phase 2 trial

Patients with cancer are at high risk for severe courses of COVID-19. Based on (pre-)clinical data suggesting a potential protective effect due to the immunomodulating properties of azithromycin, we have initi...

Source: Infectious Agents and Cancer - February 12, 2023 Category: Cancer & Oncology Authors: Maximilian J. Mair, Agnieszka Maj-Hes, Alina Nussbaumer-Pr öll, Rainer Puhr, Agnieszka Christenheit, Marlene Troch, Hannah C. Puhr, Angelika M. Starzer, Ariane Steindl, Sabine Eberl, Helmuth Haslacher, Thomas Perkmann, Christoph Minichsdorfer, Gerald W. Tags: Research Source Type: research